Skip to content

US · ICU · BIOTECHNOLOGY

SeaStar Medical Holding Corporation (ICU) intrinsic value and stock valuation

$0.94as of 2026-11-21 · Mkt cap 9.31M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SeaStar Medical Holding Corporation DCF and intrinsic value

InvestorsCraft values ICU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ICU’s statements →

SeaStar Medical Holding Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Denver, CO 80216 seastarmedical.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$1.23M
20202025
Net income
-$-12.15M
20202025
Free cash flow
-$-13.6M
20202025
Total equity
$10.4M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$1.23M$140K$0.00$0.00$0.00
Operating income-$-12.18M-$-17.84M-$-14.21M-$-11.61M-$-4.45M
Net income-$-12.15M-$-24.83M-$-26.23M-$-12.19M-$-4.6M
EPSd-$-586.11K-$-67.11M-$-291.44M-$-243.8M-$-92M
Operating cash flow-$-13.6M-$-16.01M-$-10.29M-$-7.79M-$-5.11M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-13.6M-$-16.01M-$-10.29M-$-7.79M-$-5.11M
Total assets$14.2M$4.66M$3.51M$3.04M$600K
Total debt$530K$570K$9.08M$8.83M$2.62M
Net debt-$-11.46M-$-1.25M$8.9M$8.78M$2.11M
Total equity$10.4M-$-2.18M-$-13.87M-$-20.76M-$-2.82M
Cash and short-term investments$12M$1.82M$180K$50K$510K
Income statement
20252024202320222021
Revenue$1.23M$140K$0.00$0.00$0.00
Cost of revenue$50K$0.00$0.00$0.00$0.00
Gross profit$1.18M$140K$0.00$0.00$0.00
Research and development expenses$7.52M$9.11M$5.97M$2.5M$2.77M
Selling, general and administrative expenses$5.84M$8.87M$8.04M$6.92M$1.68M
Other expenses$0.00$0.00$200K$2.19M$0.00
Operating expenses$13.4M$18M$14.2M$11.6M$4.45M
Cost and expenses$13.4M$18M$14.2M$11.6M$4.45M
Interest income$330K$100K$0.00$0.00$0.00
Interest expense$330K$240K$1.08M$630K$210K
Depreciation and amortization$20K$0.00$14M$0.00$0.00
Ebitda-$-12.16M-$-24.58M-$-11.14M-$-11.56M-$-4.38M
Operating income-$-12.18M-$-17.84M-$-14.21M-$-11.61M-$-4.45M
Total other income/expenses, net$30K-$-6.99M-$-12.02M-$-580K-$-150K
Income before tax-$-12.15M-$-24.83M-$-26.23M-$-12.19M-$-4.6M
Income tax expense$0.00$0.00$0.00$0.00-$0.00
Net income-$-12.15M-$-24.83M-$-26.23M-$-12.19M-$-4.6M
Weighted average shares outstanding$20.7M$370K$90K$50K$50K
Weighted average diluted shares outstanding$20.7M$370K$90K$50K$50K
Balance sheet
20252024202320222021
Cash and short-term investments$12M$1.82M$180K$50K$510K
Net receivables$240K$110K$0.00$0.00$60K
Inventory$70K$0.00$0.00$0.00$0.00
Total current assets$13.6M$3.77M$2.31M$1.52M$600K
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$580K$890K$1.21M$1.52M$0.00
Total assets$14.2M$4.66M$3.51M$3.04M$600K
Accounts payable$950K$3.05M$4.37M$1.93M$90K
Short-term debt$530K$570K$4.74M$1.18M$2.38M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.74M$6.84M$13.1M$16.2M$3.12M
Long-term debt$0.00$0.00$4.34M$7.65M$240K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$4.34M$7.65M$300K
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$3.74M$6.84M$17.4M$23.8M$3.42M
Common stock$0.00$0.00$10K$0.00$0.00
Retained earnings-$-151.71M-$-139.56M-$-114.73M-$-88.5M-$-76.31M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$10.4M-$-2.18M-$-13.87M-$-20.76M-$-2.82M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$530K$570K$9.08M$8.83M$2.62M
Net debt-$-11.46M-$-1.25M$8.9M$8.78M$2.11M
Cash flow statement
20252024202320222021
Net income-$-12.15M-$-24.83M-$-26.23M-$-12.19M-$-4.6M
Depreciation and amortization$20K$0.00$0.00$0.00$0.00
Stock-based compensation$620K$890K$1.93M$1.31M$10K
Change in working capital-$-2.36M$990K$2.88M$2.55M-$-680K
Accounts receivable-$-120K-$-110K$10K$0.00$0.00
Inventory-$-70K$0.00$0.00$0.00$60K
Accounts payable-$-2.1M-$-1.28M$2.44M$1.55M-$-300K
Net cash provided by operating activities-$-13.6M-$-16.01M-$-10.29M-$-7.79M-$-5.11M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$23.8M$17.4M$6.61M$10M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$23.8M$17.7M$10.4M$7.33M$2.82M
Net change in cash$10.2M$1.64M$130K-$-460K$470K
Cash at end of period$12M$1.82M$180K$50K$510K
Operating cash flow-$-13.6M-$-16.01M-$-10.29M-$-7.79M-$-5.11M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-13.6M-$-16.01M-$-10.29M-$-7.79M-$-5.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SeaStar Medical Holding Corporation

        SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.

        CEO
        Eric Schlorff
        Employees
        17
        Beta
        -1.03

        Explore

        Frequently asked questions

        What is the intrinsic value of SeaStar Medical Holding Corporation (ICU)?

        InvestorsCraft does not currently publish an intrinsic value for ICU. How the IC value is calculated.

        Is ICU undervalued?

        InvestorsCraft does not publish an undervaluation signal for ICU at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.